Yoshiyuki Tsukamoto

5PUBLICATIONS
14CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jan 29, 2026
Annexin A8 Drives MEK Inhibitor Resistance, Providing a Druggable Target for Pancreatic Ductal Adenocarcinoma.

Shusaku Kurogi, Yoshiyuki Tsukamoto, Junpei Yamamura

|Jul 13, 2024
Disulfidptosis: A Novel Prognostic Criterion and Potential Treatment Strategy for Diffuse Large B-Cell Lymphoma (DLBCL).

Yu Wang, Yoshiyuki Tsukamoto, Mitsuo Hori

|Sep 16, 2023
Association of immune-related expression profile with sensitivity to chemotherapy in esophageal squamous cell carcinoma.

Yoshiyuki Tsukamoto, Shusaku Kurogi, Hajime Fujishima

|Aug 03, 2022
Enhanced phosphorylation of c-Jun by cisplatin treatment as a potential predictive biomarker for cisplatin response in combination with patient-derived tumor organoids.

Yoshiyuki Tsukamoto, Shusaku Kurogi, Tomotaka Shibata

|Apr 29, 2021
Early response in phosphorylation of ribosomal protein S6 is associated with sensitivity to trametinib in colorectal cancer cells.

Yuka Hirashita, Yoshiyuki Tsukamoto, Yoko Kudo

Pageof 1